Pliant Therapeutics (PLRX) Interest & Investment Income (2019 - 2026)
Pliant Therapeutics (PLRX) reported Interest & Investment Income of $1.7 million for Q1 2026, down 51.46% year-over-year from $3.6 million in Q1 2025, and down 11.81% quarter-over-quarter from $2.0 million in Q4 2025.
Pliant Therapeutics (PLRX) Interest & Investment Income (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Interest & Investment Income data on file, last reported at $1.7 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $1.7 million, down 51.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.6 million (down 48.96% YoY), and the FY2025 annual result was $11.4 million, down 45.86% from the prior year.
- Interest & Investment Income eased to $1.7 million in Q1 2026 per PLRX's latest filing, from $2.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $6.5 million in Q3 2023 and troughed at $111000.0 in Q1 2022.
- A 5-year average of $3.7 million and a median of $3.6 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income surged 4276.58% in 2023, then slumped 55.59% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $2.7 million in 2022, then surged by 135.19% to $6.2 million in 2023, then decreased by 29.24% to $4.4 million in 2024, then tumbled by 55.59% to $2.0 million in 2025, then slipped by 11.81% to $1.7 million in 2026.
- Business Quant data shows PLRX's Interest & Investment Income at $1.7 million in Q1 2026, $2.0 million in Q4 2025, and $2.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -14.79 Mn |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.73 Mn |
| Dec 31, 2025 | 1.96 Mn |
| Sep 30, 2025 | 2.78 Mn |
| Jun 30, 2025 | 3.10 Mn |
| Mar 31, 2025 | 3.57 Mn |
| Dec 31, 2024 | 4.42 Mn |
| Sep 30, 2024 | 5.13 Mn |
| Jun 30, 2024 | 5.65 Mn |
| Mar 31, 2024 | 5.88 Mn |
| Dec 31, 2023 | 6.25 Mn |
| Sep 30, 2023 | 6.52 Mn |
| Jun 30, 2023 | 6.46 Mn |
| Mar 31, 2023 | 4.86 Mn |
| Dec 31, 2022 | 2.66 Mn |
| Sep 30, 2022 | 1.63 Mn |
| Jun 30, 2022 | 269,000.00 |
| Mar 31, 2022 | 111,000.00 |
| Dec 31, 2021 | 68,000.00 |
| Sep 30, 2021 | 68,000.00 |
| Jun 30, 2021 | 73,000.00 |